Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Rhythm Pharmaceuticals, Inc. (RYTM) had Income from Continuous Operations of $-196.54M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$189.76M |
|
$-201.92M |
|
$19.49M |
|
$170.26M |
|
$381.77M |
|
$-192.02M |
|
$-4.03M |
|
$-196.04M |
|
$-196.04M |
|
$-196.54M |
|
|
Income from Continuous Operations |
$-196.54M |
$-196.54M |
|
$-196.54M |
|
$-192.02M |
|
$-190.68M |
|
64.98M |
|
64.98M |
|
$-3.11 |
|
$-3.11 |
|
| Balance Sheet Financials | |
$466.92M |
|
$1.10M |
|
$13.28M |
|
$480.20M |
|
$105.94M |
|
-- |
|
$104.23M |
|
$210.17M |
|
$139.07M |
|
$264.71M |
|
$270.03M |
|
67.20M |
|
| Cash Flow Statement Financials | |
$-115.67M |
|
$-137.15M |
|
$217.96M |
|
$89.60M |
|
$54.82M |
|
$-34.78M |
|
$66.82M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.41 |
|
-- |
|
-- |
|
-- |
|
-- |
|
89.73% |
|
-101.19% |
|
-101.19% |
|
-100.49% |
|
-103.31% |
|
-106.41% |
|
$-156.63M |
|
-- |
|
-- |
|
-- |
|
0.40 |
|
0.76 |
|
7.28 |
|
50.17 |
|
-141.32% |
|
-74.25% |
|
-40.93% |
|
-72.79% |
|
$4.02 |
|
$-2.41 |
|
$-1.78 |
|